

VERIFY PATIENT INFO AND HISTORY¹

☐ Male

☐ Female

Age


☐ Patient family history of ATTR-CM

Patient family heritage or background associated with most common gene mutations in North America for hATTR:

- ☐ West African descent: Val122Ile
- ☐ Northern Ireland descent: Thr60Ala
- ☐ Swedish, Portuguese, Japanese descent: Val30Met

- ☒ No clear predominance: hATTR
- ☒ Slight male dominance: AL
- ☒ Male predominance: wtATTR

Other clinical manifestations?
Please specify

**Other clinical manifestations?**
Please specify



CHECKLIST OF SIGNS AND SYMPTOMS

Recognizing Symptoms of transthyretin amyloid cardiomyopathy ATTR-CM



When to SUSPECT ATTR-CM

Key clinical features to trigger a diagnostic workup for cardiac amyloidosis¹

SUSPECT CARDIAC AMYLOIDOSIS WHEN PATIENTS PRESENT WITH SIGNS AND SYMPTOMS OF HEART FAILURE WITH ≥ 1 OF THE FOLLOWING
(Strong Recommendation, Moderate-Quality Evidence)



Unexplained increased LV wall thickness
Older than 60 years of age with low-flow low-gradient AS and LVEF $> 40\%$




Established AL or ATTR in non-cardiac organ/system (i.e., renal AL amyloidosis causing nephrotic syndrome)



History of carpal tunnel syndrome (bilateral)



Unexplained peripheral sensorimotor neuropathy and/or dysautonomia



Adapted from Fine *et al.*¹

SUSPECT THE SIGNS OF ATTR-CM:

- ⚠ The diagnosis of ATTR-CM is often delayed or missed^{1,2}
- ⚠ It is considered a rare condition that is a potentially fatal cause of heart failure and other cardiovascular manifestations¹
- ⚠ Patients with ATTR-CM have 2-6 years of life expectancy post-diagnosis²

This checklist provides a list of extracardiac manifestations of common subtypes of cardiac amyloidosis.

Please see the CCS/CHFS guidelines for complete information.¹

ATTR-CM

SUSPECT & DETECT

Key investigational steps



BE READY TO SUSPECT ATTR-CM

VISIT ► WWW.ATTRCM.CA

PASSWORD: ATTRCM

References

1. Fine NM *et al.* Canadian Cardiovascular Society/Canadian Heart Failure Society joint position statement on the evaluation and management of patients with cardiac amyloidosis. *Can J Cardiol* 2020;36:322-34.
2. Maurer MS *et al.* Expert consensus recommendations for the suspicion and diagnosis of transthyretin cardiac amyloidosis. *Circ Heart Fail* 2019;12:e006075.



Pfizer Canada ULC
Kirkland, Quebec H9J 2M5 PP-VYN-CAN-0166-EN

